Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | AR | P10275 | 3/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 6/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30770731 | 1.00 | ATM (0.45) | ATMARKDM1AHDAC1HDAC6 | |
| Bromide SCHEMBL27949951 | 0.98 | ATM (0.44) | ATMARKDM1AHDAC1HDAC6 | |
| SCHEMBL17441422 | 0.86 | HPGD (0.47) | ARKDM1AHDAC1HDAC6MEN1 | |
| SCHEMBL1886206 | 0.83 | GSK3B (0.48) | ARKDM1AHDAC1HDAC6MAPT | |
| SCHEMBL30935127 | 0.83 | GSK3B (0.48) | ARKDM1AHDAC1HDAC6MAPT | |
| SCHEMBL1890248 | 0.81 | ACHE (0.41) | ARKDM1AHDAC1HDAC6MEN1 | |
| SCHEMBL3466469 | 0.81 | AR (0.38) | ARKDM1AHDAC1HDAC6MAPT | |
| SCHEMBL27827224 | 0.79 | AR (0.40) | ARKDM1AHDAC1HDAC6SMN1; SMN2 | |
| SCHEMBL362870 | 0.79 | UHRF1 (0.43) | ATMHDAC1HDAC6MEN1KMT2A | |
| SCHEMBL2799836 | 0.79 | KCNK3 (0.48) | ATMMEN1KMT2AMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1765503-A | Quarternary ammonium salt of quinine compound, its preparation method and use | NANJING UNIVERSITY OF TECHNOLOGY (CN) | 2006-05-03 | — | — | CN | claimed |
| WO-2024003773-A1 | 2,7-NAPHTHYRIDINE COMPOUNDS AS MASTL INHIBITORS | PFIZER INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| CN-106946775-B | Compound and application thereof in preparation of anti-hepatitis C virus medicine | 清华大学 | 2020-04-10 | — | — | CN | disclosed |
| CN-104995183-B | Novel phosphodiesterase type 10A inhibitor compounds | 艾伯维公司 | 2018-04-06 | — | — | CN | disclosed |
| CN-105348299-B | Fused tricyclic compounds as RAF kinase inhibitors | 百济神州有限公司 | 2017-12-15 | — | — | CN | disclosed |
| CN-105348299-A | Condensed tricyclic compounds as RAF kinase inhibitors | BEIGENE LTD | 2016-02-24 | — | — | CN | disclosed |
| EP-2346868-B1 | AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-01-27 | — | — | EP | disclosed |
| EP-2346868-B1 | AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-01-27 | — | — | EP | disclosed |
| CN-103596926-B | Fused tricyclic compounds as RAF kinase inhibitors | BEIGENE, LTD. (KY) | 2015-11-25 | — | — | CN | disclosed |
| US-8927550-B2 | Heterocyclic compounds as CCR1 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| US-20100093703-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093703-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
| WO-2010036632-A1 | AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010036632-A1 | AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |
| EP-2121600-A2 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | Boehringer Ingelheim International GmbH (DE) | 2009-11-25 | — | — | EP | disclosed |
| CN-101410387-A | Pyridyl-and pyrimidinyl-substituted pyrrole-, thiophene-and furan-derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES SRL (IT) | 2009-04-15 | — | — | CN | disclosed |
| WO-2008099000-A2 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008099000-A2 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-08-21 | — | — | WO | disclosed |
| CN-101123964-A | G-protein coupled receptor (GPR116) agonists and their use for the treatment of obesity and diabetes | PROSIDION LTD (GB) | 2008-02-13 | — | — | CN | disclosed |
| CN-1765503-A | Quarternary ammonium salt of quinine compound, its preparation method and use | NANJING UNIVERSITY OF TECHNOLOGY (CN) | 2006-05-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093703-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | PYGL, PYGM, G6PC1 | ATM 2439/4885AR 3341/4885KDM1A 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.